[go: up one dir, main page]

MX2009010962A - Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo. - Google Patents

Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.

Info

Publication number
MX2009010962A
MX2009010962A MX2009010962A MX2009010962A MX2009010962A MX 2009010962 A MX2009010962 A MX 2009010962A MX 2009010962 A MX2009010962 A MX 2009010962A MX 2009010962 A MX2009010962 A MX 2009010962A MX 2009010962 A MX2009010962 A MX 2009010962A
Authority
MX
Mexico
Prior art keywords
alkyl group
compound
lower alkyl
hydrogen atom
medicine
Prior art date
Application number
MX2009010962A
Other languages
English (en)
Inventor
Toru Miura
Tadaaki Ohgiya
Ayumu Okuda
Koichi Yamazaki
Haruki Shibata
Toshiharu Arai
Taro Aoki
Katsutoshi Miyosawa
Shibuya Kimiyuki
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2009010962A publication Critical patent/MX2009010962A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto representado por la siguiente fórmula general (I) en donde R1, R2, R3, R4 y R5 representan átomo de hidrógeno, un grupo halo(alquilo inferior), grupo ciano y similar, R6 representa un grupo alquilo, un grupo cicloalquilo y similar, R7, R8, R9 y R10 representan átomo de hidrógeno, un átomo de halógeno, un grupo alquilo inferior, un grupo halo(alquilo inferio) y similares, R11 y R12 representan átomo de hidrógeno, un grupo alquilo inferior, un grupo (çicloalquilo inferior) (alquilo inferior) y similares, y R13 representa átomo de hidrógeno, un átomo de halógeno, un grupo alcoxi inferior y similar, que tiene actividad inhibitoria potente de la proteína de transferencia de éster de colesterol (CETP). (ver fórmula (I)).
MX2009010962A 2007-04-13 2008-04-10 Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo. MX2009010962A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91162007P 2007-04-13 2007-04-13
PCT/JP2008/057058 WO2008129951A1 (ja) 2007-04-13 2008-04-10 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬

Publications (1)

Publication Number Publication Date
MX2009010962A true MX2009010962A (es) 2009-12-16

Family

ID=39875479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010962A MX2009010962A (es) 2007-04-13 2008-04-10 Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.

Country Status (19)

Country Link
US (1) US7659271B2 (es)
EP (1) EP2149563B9 (es)
JP (2) JP5244095B2 (es)
KR (1) KR101501299B1 (es)
CN (1) CN101679309B (es)
AU (1) AU2008241904B2 (es)
BR (1) BRPI0810880A2 (es)
CA (1) CA2683534C (es)
DK (1) DK2149563T3 (es)
EA (1) EA017321B1 (es)
ES (1) ES2533910T3 (es)
HU (1) HUE024898T2 (es)
IL (1) IL201402A (es)
MX (1) MX2009010962A (es)
NZ (1) NZ580777A (es)
PL (1) PL2149563T3 (es)
PT (1) PT2149563E (es)
TW (1) TWI439453B (es)
WO (1) WO2008129951A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) * 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
JP5319457B2 (ja) * 2008-08-25 2013-10-16 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
JPWO2010029756A1 (ja) * 2008-09-12 2012-02-02 興和株式会社 ５−［２−（メチルチオ）エトキシ］ピリミジン−２−アミンの製造方法
US8841478B2 (en) 2008-11-28 2014-09-23 Kowa Company, Ltd. Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester
CN102933559B (zh) * 2010-06-04 2016-01-27 兴和株式会社 光学活性二苄胺衍生物及其制备方法
CN105837401A (zh) 2010-07-22 2016-08-10 兴和株式会社 光学活性1-溴-1-［3,5-双（三氟甲基）苯基］乙烷的制备方法
JPWO2012046681A1 (ja) * 2010-10-04 2014-02-24 興和株式会社 脂質代謝関連ｍＲＮＡの発現抑制剤
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
US20140303198A1 (en) * 2011-11-29 2014-10-09 Kowa Company, Ltd. Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
WO2013081087A1 (ja) * 2011-12-02 2013-06-06 興和株式会社 光学活性化合物の製造方法
JP5555303B2 (ja) * 2011-12-02 2014-07-23 興和株式会社 光学活性ジベンジルアミン誘導体及びその製造方法
WO2013137371A1 (ja) * 2012-03-15 2013-09-19 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
WO2014017569A1 (ja) * 2012-07-26 2014-01-30 興和株式会社 血中ｌｄｌを低下させるための医薬
US9682942B2 (en) 2013-05-31 2017-06-20 Kowa Company, Ltd. Form of pyrimidine compound having dibenzylamine structure
CN104628584B (zh) * 2013-11-08 2017-03-08 广州朗圣药业有限公司 一种适合工业化的高纯度达泊西汀的制备方法
EP3225240A4 (en) * 2014-11-28 2018-06-06 Kowa Company, Ltd. Medicine
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
JP2003221376A (ja) 2001-11-21 2003-08-05 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤
IL162870A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
EP1829858A3 (en) * 2002-08-30 2007-10-03 Japan Tobacco, Inc. Dibenzylamine compounds and pharmaceutical use thereof
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
US7737295B2 (en) * 2004-04-13 2010-06-15 Merck Sharp & Dohme Corp. CETP inhibitors
AR053784A1 (es) * 2004-11-23 2007-05-23 Pfizer Prod Inc Compuestos y derivados tetrazolicos de dibencil amina. composiciones farmaceuticas.
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN103102303B (zh) * 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
WO2006098394A1 (ja) 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
EP1942904A4 (en) 2005-09-30 2009-11-18 Merck & Co Inc CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
AU2006330072B2 (en) 2005-12-28 2012-08-02 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
JP5225076B2 (ja) 2006-04-27 2013-07-03 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途
EP2024356A1 (en) 2006-05-10 2009-02-18 Novartis AG Bicyclic derivatives as cetp inhibitors
US7750019B2 (en) * 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) * 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors

Also Published As

Publication number Publication date
IL201402A (en) 2015-10-29
KR20100016332A (ko) 2010-02-12
DK2149563T3 (en) 2015-02-02
CN101679309B (zh) 2012-02-29
WO2008129951A1 (ja) 2008-10-30
JP2013129678A (ja) 2013-07-04
AU2008241904A1 (en) 2008-10-30
BRPI0810880A2 (pt) 2016-07-19
CA2683534C (en) 2015-02-24
EP2149563B1 (en) 2015-01-07
AU2008241904B2 (en) 2012-06-07
PT2149563E (pt) 2015-02-18
HK1138274A1 (en) 2010-08-20
US7659271B2 (en) 2010-02-09
EP2149563A4 (en) 2011-09-07
PL2149563T3 (pl) 2015-06-30
JPWO2008129951A1 (ja) 2010-07-22
US20090082352A1 (en) 2009-03-26
KR101501299B1 (ko) 2015-03-10
HUE024898T2 (en) 2016-02-29
NZ580777A (en) 2011-05-27
EP2149563B9 (en) 2015-04-22
EP2149563A1 (en) 2010-02-03
TWI439453B (zh) 2014-06-01
EA017321B1 (ru) 2012-11-30
EA200970943A1 (ru) 2010-04-30
ES2533910T3 (es) 2015-04-15
IL201402A0 (en) 2010-05-31
TW200906804A (en) 2009-02-16
CA2683534A1 (en) 2008-10-30
CN101679309A (zh) 2010-03-24
JP5244095B2 (ja) 2013-07-24

Similar Documents

Publication Publication Date Title
MX2009010962A (es) Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
WO2008111604A1 (ja) 新規なベンジル（ヘテロサイクリックメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
UA105185C2 (uk) Піроли
PH12013501873A1 (en) Novel imidazo-oxazine compound or salt thereof
WO2008078678A1 (ja) オキシムエステル化合物及び該化合物を含有する光重合開始剤
TW200738685A (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
UA90269C2 (ru) Тетрагидрохинолиновые производные и способ их получения
MX2009010814A (es) Compuestos de hidrazida y agente controlador de artropodos dañinos que contiene el mismo.
MX343225B (es) Nuevos derivados de aril-benzocicloalquil-amida.
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
PH12012502033A1 (en) Pesticidal composition and its use
PH12012501125A1 (en) 3, 4, 4a, 10b - tetrahydro -1h- thiopyrano -[4, 3-c] isoquinoline derivatives
MX2013005753A (es) Nuevos derivados de biaril amida.
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
TW200732281A (en) Heterocyclic CETP inhibitors
MX2007003872A (es) Nuevos derivados bis-azaindolicos, preparacion y su uso farmaceutico de los mismos como inhibidores de cinasas.
NZ595890A (en) Pyrazole compound
MX2012001067A (es) Procesos para la alquilacion de pirazoles.
HRP20110780T1 (hr) Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6
MX342390B (es) Proceso para preparar 3-haloalquilpirazoles.
MX342311B (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).

Legal Events

Date Code Title Description
FG Grant or registration